Edition:
India

Abcam PLC (ABCA.L)

ABCA.L on London Stock Exchange

1,174.00GBp
8:56pm IST
Change (% chg)

2.00 (+0.17%)
Prev Close
1,172.00
Open
1,191.00
Day's High
1,192.00
Day's Low
1,168.00
Volume
382,474
Avg. Vol
410,788
52-wk High
1,523.00
52-wk Low
1,006.00

Latest Key Developments (Source: Significant Developments)

Abcam Says CFO Gavin Wood To Step Down
Monday, 22 Jul 2019 

July 22 (Reuters) - Abcam PLC ::ABCAM PLC - ITS CHIEF FINANCIAL OFFICER, GAVIN WOOD, HAS TODAY SERVED NOTICE OF HIS INTENTION TO STEP DOWN.ABCAM PLC - SEARCH FOR WOOD'S SUCCESSOR WILL COMMENCE IMMEDIATELY.  Full Article

Abcam Sees FY Rev, Gross Margin To Be Higher Than Last Yr
Monday, 22 Jul 2019 

July 22 (Reuters) - Abcam PLC ::FULL YEAR TRADING UPDATE.EXPECTS TO REPORT FY TOTAL REVENUE OF £259.9 MILLION (2017/18: £233.2 MILLION).SEES FY GROSS MARGIN TO BE AHEAD OF LAST YEAR AND ADJUSTED EBITDA MARGIN TO BE IN LINE WITH BOARD'S EXPECTATIONS.CURRENTLY REVIEWING ITS PLANS FOR NEXT FIVE YEARS TO 2023/24.  Full Article

Abcam PLC Announces Acquisition Of Cell Lines And Lysates Portfolio
Tuesday, 16 Jul 2019 

July 16 (Reuters) - Abcam PLC ::ABCAM PLC - ACQUISITION OF CELL LINES AND LYSATES PORTFOLIO.ABCAM - FINANCIAL TERMS OF DEAL HAVE NOT BEEN DISCLOSED AND ARE EXPECTED TO HAVE A MINIMAL IMPACT ON REVENUE AND EARNINGS IN CURRENT FINANCIAL YEAR.  Full Article

Entities Affiliated With Standard Life Aberdeen Disclose 5.08 Pct Stake In Abcam
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Abcam PLC ::ENTITITES AFFILIATED WITH STANDARD LIFE ABERDEEN DISCLOSE 5.08 PERCENT STAKE IN ABCAM PLC AS OF MAR. 8 - FILING.  Full Article

Abcam Says Implementing Contingency Plans Ahead Of Potential 'No-Deal' Brexit
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Abcam PLC ::DOUBLE-DIGIT GROWTH DELIVERED IN H1; ON TRACK TO ACHIEVE FY19 GOALS.GROUP EXPECTS TO REPORT TOTAL REVENUE GROWTH FOR FIRST HALF OF APPROXIMATELY 11% ON A REPORTED BASIS.EXPECTS TO REPORT GROSS MARGIN FOR FIRST HALF MODESTLY AHEAD OF LAST YEAR, IN LINE WITH BOARD'S EXPECTATIONS.GROUP HAS BEGUN IMPLEMENTING CONTINGENCY PLANS AHEAD OF A POTENTIAL 'NO-DEAL' BREXIT IN ORDER TO MINIMISE RISK OF DISRUPTION TO CUSTOMERS.  Full Article

Abcam Says FY Pretax Profit Rose 33.1 Pct To 69.1 Mln Stg
Monday, 10 Sep 2018 

Sept 10 (Reuters) - Abcam PLC ::FY PRETAX PROFIT ROSE 33.1 PERCENT TO 69.1 MILLION STG.FY REVENUE ROSE 7.4 PERCENT TO 233.2 MILLION STG.LONG-TERM MARKET OUTLOOK REMAINS POSITIVE; GOOD MOMENTUM ACROSS BUSINESS.PROPOSED FINAL DIVIDEND OF 8.58P (2016/17: 7.36P) FOR FY.AMBITION TO MAINTAIN REVENUE GROWTH AT LOW DOUBLE-DIGIT RATES OVER MEDIUM-TERM.ANTICIPATE 2018/19 ADJUSTED EBITDA MARGIN OF ABOUT 36 PCT AS A RESULT OF INCREASED INVESTMENT IN STRATEGIC INITIATIVES.EXPECT TOTAL CONSTANT CURRENCY REVENUE GROWTH FOR 2018/19 OF ABOUT 11 PCT.  Full Article

Abcam Expects FY Rev At Constant Currency To Rise 10.7 Pct
Thursday, 12 Jul 2018 

July 12 (Reuters) - Abcam PLC ::EXPECT TO REPORT REVENUE GROWTH FOR YEAR OF 10.7% ON A CONSTANT CURRENCY BASIS AND 7.4% ON A REPORTED BASIS.FY GROUP REPORTED GROSS MARGIN IS EXPECTED TO BE BROADLY IN LINE WITH LAST YEAR (FY2017: 70.1%).EXPECTS TO DELIVER AN ADJUSTED EBITDA MARGIN IN LINE WITH BOARD'S EXPECTATIONS FOR FY.  Full Article

Abcam Says Entered Into License Agreement With Roche​
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Abcam Plc ::‍HAS ENTERED INTO A DEFINITIVE LICENSE AGREEMENT WITH ROCHE​.‍WILL OBTAIN EXCLUSIVE RIGHTS TO PRODUCT PORTFOLIO OF SPRING BIOSCIENCE CORPORATION IN RESEARCH USE ONLY (RUO) FIELD OF USE.ROCHE TO RETAIN ANTIBODY DEVELOPMENT CAPABILITIES, RIGHTS TO SPRING PORTFOLIO FOR INTERNAL RESEARCH, COMPANION DIAGNOSTIC, IVD USES​​.ALL PRODUCTS TO BE SOLD UNDER ABCAM BRAND, INCLUSIVE OF SP BRANDING, ARE EXPECTED TO BE AVAILABLE THROUGH ABCAM.COM FROM 21 FEBRUARY 2018​.GRANTED EXCLUSIVE RUO RIGHTS FOR FUTURE PRODUCTS DEVELOPED BY SPRING THAT ROCHE REQUESTS TO BE COMMERCIALISED IN RUO FIELD OF USE FOR INITIAL PERIOD OF 10 YEARS.‍FINANCIAL TERMS OF AGREEMENT HAVE NOT BEEN DISCLOSED​.  Full Article

Abcam Says Signed Exclusive License Agreement with Roche
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Abcam Plc ::‍HAS ENTERED INTO A DEFINITIVE LICENSE AGREEMENT WITH ROCHE​.‍WILL OBTAIN EXCLUSIVE RIGHTS TO PRODUCT PORTFOLIO OF SPRING BIOSCIENCE CORPORATION ("SPRING") IN RESEARCH USE ONLY (RUO) FIELD OF USE​.‍WILL RETAIN ANTIBODY DEVELOPMENT CAPABILITIES AND RIGHTS PERTAINING TO SPRING PORTFOLIO FOR INTERNAL RESEARCH, COMPANION DIAGNOSTIC AND IVD USES​.‍ALL PRODUCTS WILL BE SOLD UNDER ABCAM BRAND, INCLUSIVE OF SP BRANDING, AND ARE EXPECTED TO BE AVAILABLE THROUGH ABCAM.COM FROM 21 FEBRUARY 2018​.‍HAS ALSO BEEN GRANTED EXCLUSIVE RUO RIGHTS FOR ALL FUTURE PRODUCTS DEVELOPED BY SPRING THAT ROCHE REQUESTS TO BE COMMERCIALISED IN RUO FIELD OF USE FOR AN INITIAL PERIOD OF 10 YEARS.‍FINANCIAL TERMS OF AGREEMENT HAVE NOT BEEN DISCLOSED​.  Full Article

Abcam Says On Track TO DELIVER 10% FY CONSTANT CURRENCY REVENUE GROWTH
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Abcam Plc ::ABCAM PLC - WE EXPECT TO REPORT REVENUE GROWTH FOR FIRST HALF OF APPROXIMATELY 11 PCT.ABCAM PLC - REMAIN ON TRACK TO DELIVER AGAINST OUR CONSTANT CURRENCY REVENUE GROWTH TARGET OF AROUND 10% FOR FULL YEAR.ABCAM PLC - CATALOGUE REVENUE GREW BY OVER 11% IN FIRST HALF OF YEAR.  Full Article